Association Between Pancreatic Cancer and Dipeptidyl Peptidase-4 Inhibitors Use in a Case-Control Study
Dipeptidyl peptidase-4 inhibitor is an incretin-based agent used to treat type 2 diabetes mellitus, which has been available in the Taiwan market since 2009.1 Pancreatic cancer was the eighth leading cause of cancer death in Taiwan in 2017.2 At present, no definite evidence is available on the association between pancreatic cancer and dipeptidyl peptidase-4 inhibitors in Taiwan. To evaluate this issue, a population-based case-control study was conducted using the database of the Taiwan National Health Insurance Program with 23 million citizens living in the independent country of Taiwan.
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Shih-Wei Lai, Cheng-Li Lin, Kuan-Fu Liao Tags: Letter to the Editor Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Health Insurance | Incretin Therapy | Insurance | Internal Medicine | Pancreas | Pancreatic Cancer | Study | Taiwan Health